Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer

Gastric Cancer Clinical Trial

Official title:

A Phase II Combination Trial of PS-341 and 5-FU/LV in Gastric and/or GE Junction Adenocarcinoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00103103
• Other study ID #: CDR0000410827
• Secondary ID: CCC-PHII-43NCI-5
• Status: Terminated
• Phase: Phase 2
• First received: February 7, 2005
• Last updated: October 11, 2010
• Start date: March 2005
• Est. completion date: August 2005

Study information

• Verified date: October 2010
• Source: California Cancer Consortium
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with fluorouracil and leucovorin may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving bortezomib together with fluorouracil and leucovorin works in treating patients with metastatic or unresectable stomach cancer.

Description:

OBJECTIVES:

Primary

• Determine response in patients with previously treated metastatic or unresectable gastric or gastroesophageal junction adenocarcinoma treated with bortezomib, fluorouracil, and leucovorin calcium.

Secondary

• Determine time to progression and overall survival of patients treated with this regimen.

• Determine the toxic effects of this regimen in these patients.

OUTLINE: This is a non-randomized, multicenter study.

Patients receive bortezomib IV over 3-5 seconds on days 1, 8, and 15. One hour after completion of bortezomib, patients receive leucovorin calcium IV and fluorouracil IV followed by fluorouracil IV continuously over 46 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for survival.

PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 0
• Est. completion date: August 2005
• Est. primary completion date: August 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of gastric or gastroesophageal junction adenocarcinoma

• Metastatic or unresectable disease

• Progressive disease after receiving 1 prior chemotherapy regimen for metastatic disease comprising 1 of the following:

• Fluorouracil

• Cisplatin and irinotecan

• Capecitabine

• Taxanes

• Measurable disease

• No esophageal cancer

• No brain metastases

PATIENT CHARACTERISTICS:

Age

• Over 18

Performance status

• ECOG 0-2 OR

• Karnofsky 60-100%

Life expectancy

• At least 3 months

Hematopoietic

• Absolute neutrophil count = 1,500/mm^3

• Platelet count = 100,000/mm^3

Hepatic

• Bilirubin normal

• AST and ALT = 2.5 times upper limit of normal

Renal

• Creatinine = 1.5 mg/dL

Cardiovascular

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No cardiac arrhythmia

• No acute ischemia by EKG

• No significant conduction abnormality by EKG, including either of the following:

• Bifasicular block, defined as left anterior hemiblock in the presence of right bundle branch block

• Second or third degree atrioventricular block

• No history of cardiac or cerebrovascular disease due to hypotension and tachycardia

Other

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception before, during, and for 6 months after study participation

• No ongoing or active infection

• No other uncontrolled illness

• No peripheral neuropathy = grade 2 within the past 2 weeks

• No allergy to boron or mannitol

PRIOR CONCURRENT THERAPY:

Biologic therapy

• More than 4 weeks since prior immunotherapy

Chemotherapy

• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

Endocrine therapy

• Not specified

Radiotherapy

• More than 4 weeks since prior radiotherapy and recovered

Surgery

• More than 2 weeks since prior major surgery

Other

• No concurrent highly active anti-retroviral therapy for HIV-positive patients

• No other concurrent investigational agents

Study Design

Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• bortezomib

• fluorouracil

• leucovorin calcium

Locations

Country	Name	City	State
United States	City of Hope Comprehensive Cancer Center	Duarte	California
United States	USC/Norris Comprehensive Cancer Center and Hospital	Los Angeles	California
United States	City of Hope Medical Group	Pasadena	California
United States	Hillman Cancer Center at University of Pittsburgh Cancer Institute	Pittsburgh	Pennsylvania
United States	University of California Davis Cancer Center	Sacramento	California

Sponsors (2)

Lead Sponsor	Collaborator
California Cancer Consortium	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate as measured by RECIST every 8 weeks			No
Secondary	Time to progression every 8 weeks			No
Secondary	Overall survival			No
Secondary	Toxicity every 4 weeks			Yes
Secondary	Molecular correlates on and off study treatment			No